Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is a global commercial-stage biopharmaceutical company developing medicines for rare neuroendocrine diseases, with a focus on melanocortin-4 receptor (MC4R) pathway disorders that can cause severe obesity and insatiable hunger. Its marketed product, IMCIVREE (setmelanotide),… From the company’s description.
In fiscal 2025, Rhythm Pharmaceuticals, Inc. reported revenue of $189.76M, up 45.8% from fiscal 2024, and a net loss of $196.54M. Its operating margin was −101.2%, and operations used $115.67M in cash. Over the twelve months to Jun 30, 2026, revenue was $239.92M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rhythm Pharmaceuticals, Inc. does
In the company’s own words
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is a global commercial-stage biopharmaceutical company developing medicines for rare neuroendocrine diseases, with a focus on melanocortin-4 receptor (MC4R) pathway disorders that can cause severe obesity and insatiable hunger. Its marketed product, IMCIVREE (setmelanotide), is approved in the United States and several other markets for certain genetic forms of obesity, including Bardet-Biedl syndrome and deficiencies involving POMC, PCSK1 or LEPR. The company is also developing setmelanotide for additional conditions, including hypothalamic obesity and Prader-Willi syndrome, and has two investigational MC4R agonists: oral bivamelagon and weekly injectable RM-718. Its customers and intended beneficiaries include patients with these rare diseases and the healthcare providers who treat them. Rhythm’s business centers on its MC4R agonist programs; the company does not describe separate reportable business segments in the supplied text. It had 414 employees as of February 1, 2026, including 126 outside North America.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1649904
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rhythm Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Rhythm Pharmaceuticals, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Rhythm Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rhythm Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rhythm Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rhythm Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”